Abstract
BackgroundDaily oral and pericoital tenofovir-based antiretroviral pre-exposure prophlyaxis (PrEP), reduced risk of HIV-1 acquisition in trials among high risk populations; oral emtricitabine(FTC)/tenofovir (TDF) received a label indication for HIV-1 prevention....
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have